SAB BIOTHERAPEUTICS, INC. (SABS) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $8.00K; Additional Paid in CapitalUSD $373.48M; Treasury Stock, ValueUSD $5.52M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $7.58K; Additional Paid in CapitalUSD $362.75M; Treasury Stock, ValueUSD $5.52M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $267.72M; Treasury Stock, ValueUSD $5.52M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $4.76K; Additional Paid in CapitalUSD $264.55M; Treasury Stock, ValueUSD $5.52M.
SAB BIOTHERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $8.00K | $373.48M | $5.52M | $-930.00K | $-152.25M | $214.78M | 54.66K | 3 month · $7.25M | (m) | (m) |
| 2026-03-31 | (m) | $7.58K | $362.75M | $5.52M | $-222.76K | $-129.76M | $227.25M | 54.66K | 3 month · $5.46M | (m) | (m) |
| 2025-12-31 | (m) | $5.00K | $267.72M | $5.52M | $187.00K | $-110.89M | $151.50M | 54.66K | 12 month · $5.21M | (m) | (m) |
| 2025-09-30 | (m) | $4.76K | $264.55M | $5.52M | $71.22K | $-94.03M | $165.07M | 54.66K | 3 month · $800.76K | (m) | (m) |
| 2025-06-30 | $5.00 | $936.00 | $157.03M | $5.52M | $-15.80K | $-139.48M | $12.02M | 54.66K | 3 month · $627.00K | (m) | (m) |
| 2025-03-31 | $5.00 | $936.00 | $156.41M | $5.52M | $-111.59K | $-129.37M | $21.41M | 54.66K | 3 month · $613.00K | (m) | (m) |
| 2024-12-31 | $5.00 | $935.00 | $155.79M | $5.52M | $-135.41K | $-124.17M | $25.97M | 54.66K | 12 month · $2.94M | (m) | (m) |
| 2024-09-30 | $5.00 | $929.00 | $155.14M | $5.52M | $52.13K | $-112.77M | $36.90M | 54.66K | 3 month · $1.05M | (m) | (m) |
| 2024-06-30 | $5.00 | $929.00 | $154.10M | $5.52M | $-31.35K | $-102.42M | $46.12M | 54.66K | 3 month · $601.43K | (m) | (m) |
| 2024-03-31 | $5.00 | $929.00 | $153.49M | $5.52M | $-63.45K | $-95.09M | $52.82M | 54.66K | 3 month · $617.45K | (m) | (m) |
| 2023-12-31 | $5.00 | $929.00 | $152.86M | $5.52M | $26.42K | $-90.06M | $57.30M | 54.66K | 12 month · $2.42M | 12 month · $3.83M | (m) |
| 2023-09-30 | (m) | $5.29K | $87.98M | $5.52M | (m) | $-67.21M | $15.26M | 546.66K | 3 month · $639.25K | (m) | (m) |
| 2023-06-30 | $0.00 | $5.29K | $87.34M | $5.52M | (m) | $-62.10M | $19.72M | 546.66K | 3 month · $644.82K | (m) | (m) |
| 2023-03-31 | $0.00 | $5.09K | $85.14M | $5.52M | (m) | $-55.22M | $24.40M | 546.66K | 3 month · $602.78K | 3 month · $93.53K | (m) |
| 2022-12-31 | $0.00 | $510.00 | $84.45M | $5.52M | (m) | $-47.87M | $31.06M | 54.66K | 12 month · $2.67M | (m) | 546.66K |
| 2022-09-30 | (m) | $4.36K | $76.14M | $5.52M | (m) | $-40.00M | $30.62M | (m) | 3 month · $578.20K | (m) | 546.66K |
| 2022-06-30 | $0.00 | $4.36K | $75.56M | $5.52M | (m) | $-32.92M | $37.12M | (m) | 3 month · $569.86K | (m) | 546.66K |
| 2022-03-31 | $0.00 | $4.35K | $74.92M | $5.52M | (m) | $-28.14M | $41.26M | (m) | 3 month · $897.60K | (m) | 546.66K |
| 2021-12-31 | $0.00 | $4.35K | $67.67M | $0.00 | (m) | $-29.13M | $38.55M | (m) | 12 month · $2.31M | (m) | 0.00 |
| 2021-09-30 | (m) | $330.00 | (m) | (m) | (m) | $-9.29M | $35.08M | (m) | 3 month · $880.66K | (m) | (m) |
| 2021-06-30 | (m) | $330.00 | $4.24M | (m) | (m) | $-8.96M | $38.26M | (m) | 3 month · $433.43K | (m) | (m) |
| 2021-03-31 | (m) | $330.00 | $2.04M | (m) | (m) | $-6.76M | $40.77M | (m) | 3 month · $349.12K | 3 month · $7.03M | (m) |
| 2021-01-14 | (m) | $330.00 | $5.36M | (m) | (m) | $-10.02M | $-10.02M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $0.00 | $2.60K | $50.99M | (m) | (m) | $-11.98M | $39.01M | (m) | 12 month · $1.30M | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $7.69M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |